Lanthi-angiotensins
Endogenous overstimulation of the so-called detrimental arm of the Renin-Angiotensin System (RAS) plays an important role in the initiation and progression of cardiovascular, renal and other diseases. In contrast, stimulation of so-called protective RAS, especially AT2- or Mas receptors, may counterbalance the detrimental effects and offers a novel strategy for treatment of diseases with high unmet medical need. Lanthio Pharma has discovered lanthionine-constrained agonists of the protective RAS receptors, subject of three development programs.